Patients were enrolled in this trial on the basis of the results of circulating cell-free tumor DNA (ctDNA) testing, either by digital PCR or targeted sequencing.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Currently, fulvestrant plus palbociclib is approved by the FDA in the metastatic breast cancer setting only following disease progression on endocrine therapy.
This phase 3 study compared endocrine therapy with or without abemaciclib in patients with high-risk, early-stage, hormone receptor-positive, HER2-negative breast cancer.
There was no benefit to adding palbociclib to adjuvant endocrine therapy for treatment of early HR+, HER2- breast cancer vs endocrine therapy alone, according to a results from PALLAS.
When should women begin getting mammograms? Guidance can vary based on an individual’s family history or other high-risk identifiers, but physicians advise that women get screened for breast cancer consistently by at least age 50. However, a recent study out of the United Kingdom suggests that starting breast cancer screenings earlier could have a large…
Findings showed atezolizumab in combination with paclitaxel did not meet statistical significance for progression free survival and also demonstrated a negative trend in overall survival.
Older patients with early-stage breast cancer who were treated with an oncogeriatric approach were more likely to receive adjuvant treatments and had improved clinical outcomes.
Pooled data from 2 randomized trials evaluating endocrine therapy +/- a CDK4/6 inhibitor were used to investigate whether BMI influenced patient outcomes in MBC.
A retrospective review of women treated for breast cancer diagnosed in 2010-2016 demonstrated the effects of delays in time to surgery for DCIS and cT1-2N0 disease.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
This analysis focused on whether pCR is a prognostic biomarker in the setting of an adaptive, randomized, platform trial evaluating neoadjuvant breast cancer therapy.
A team of investigators conducted a multicenter cohort study to determine if a relationship existed between treatment for hyperthyroidism and risk of death from solid cancer.
